Key result
LAAC yields ~40% lower 10-year costs versus NOACs for stroke prevention in NVAF.
Why the study?
The study was designed to determine the relative costs to Medicare and Medicare beneficiaries of warfarin, NOACs, and LAAC for stroke risk reduction in nonvalvular atrial fibrillation.
Does left atrial appendage closure (LAAC) reduce costs to Medicare and patients compared to warfarin and NOACs in nonvalvular atrial fibrillation?
Does left atrial appendage closure (LAAC) reduce costs to Medicare and patients compared to warfarin and NOACs in nonvalvular atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Left atrial appendage closure yields lower long-term overall and patient out-of-pocket costs compared to NOACs and warfarin for stroke prophylaxis in nonvalvular atrial fibrillation.
Background: payers and patients. Objective: To determine the relative costs to Medicare and Medicare beneficiaries (patients) of warfarin, non-vitamin K oral anticoagulants (NOACs), and left atrial appendage closure (LAAC) for stroke risk reduction in nonvalvular atrial fibrillation. Methods: trial results. The model captured therapy costs vs clinical event costs, including procedural complications and follow-up clinical outcomes. Costs were based on 2023 Medicare reimbursement and copayment rates. Results: At 10 years, overall LAAC costs ($48,337) were lower than those of NOACs ($81,198) and warfarin ($52,359). Overall LAAC costs were lower than those of NOACs by year 5 and warfarin by year 9. At 5 years, patient LAAC costs were lowest at $4,764, compared to $7,146 and $6,453 for NOACs and warfarin, respectively. LAAC patient costs were lower than those of NOACs by year 3 and warfarin by year 4. Clinical events comprised 96% of overall warfarin costs vs 48% for LAAC and 40% for NOACs. Conclusion: LAAC yielded the lowest overall and patient costs. Warfarin costs were largely driven by clinical events, which may represent an unplanned financial burden for patients. These considerations should be incorporated into shared decision-making discussions about stroke prophylaxis strategies.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2024) studied nonvalvular atrial fibrillation. Left atrial appendage closure (LAAC) vs. NOACs and warfarin was evaluated on Overall costs to Medicare and Medicare beneficiaries at 10 years. Left atrial appendage closure yielded lower overall 10-year costs ($48,337) compared to NOACs ($81,198) and warfarin ($52,359) for stroke risk reduction in nonvalvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: